Doesn't really say much about the effectiveness of the tratment
BioMS Medical's pivotal Multiple Sclerosis trial receives third positive review from Data Safety Monitoring Board 07 February 2006
EDMONTON, Feb. 7 /CNW/ - BioMS Medical Corp. a leading developer in the treatment of multiple sclerosis (MS), today announced that following the third meeting of the independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis.
"The DSMB reviewed safety data from our trial, including data from MRI scans conducted on the first 100 patients dosed in study, who are undergoing an extensive safety analysis as per the trial design," said Kevin Giese, President of BioMS Medical. "This third positive recommendation by the DSMB members highlights the steady progress being made in advancing our pivotal trial."
This was the third of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial. The pivotal phase II/III study is now ongoing at trial sites across Canada, the U.K. and Sweden.
Source: BioMS Medical Corp.